title: Cellular basis of the resistance of newborn mice to the pathogenic effects of anti-CD3 treatment.
abstract: We have analysed the mechanisms underlying the differences in the susceptibilities of adult and newborn mice to the pathogenic effects of anti-CD3 mAbs. Our data show that the thymus cell number in adults is reduced by 93% 48 h after one single injection of 5 mg/kg of Ab whereas the same dose in newborns induces only a 30% decrease. In the adult, this effect is associated with a marked depletion of CD4+ CD8+ double positive (DP) cells and with the appearance of important areas of cell necrosis in the thymic cortex. In newborns, the DP cells are less affected and the thymic cortex does not present any cell necrosis even after an injection of 45 mg/kg of mAbs. Pre-treatment of adults with anti-CD4 and anti-CD8 Abs, while completely abolishing the toxic side-effects induced by anti-CD3 mAbs, does not protect the thymus from the depletion of DP cells. In vitro, anti-CD3 mAbs induce the proliferation of thymocytes and spleen cells from adults but not from newborns. Tumour necrosis factor-alpha (TNF alpha) is found in the serum of adults 90 min after injection of anti-CD3 but is never detected in the serum of anti-CD3 treated newborns. Taken together our data support the view that anti-CD3 mAbs act by two different mechanisms. The first one results from the binding of anti-CD3 on the CD3+ thymocytes which induces a direct toxicity for only the CD4+ CD8+ cells.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Département d'Immunologie, Institut Pasteur (URA CNRS 359 and Université P & M Curie, Paris, France.
authors.forename: D
authors.initials: D
authors.lastname: Rueff-Juy
authors.forename: I
authors.initials: I
authors.lastname: Liberman
authors.forename: A M
authors.initials: AM
authors.lastname: Drapier
authors.forename: J C
authors.initials: JC
authors.lastname: Guillon
authors.forename: C
authors.initials: C
authors.lastname: Leclerc
authors.forename: P A
authors.initials: PA
authors.lastname: Cazenave
mesh_terms: D000367:Age Factors; D000818:Animals; D000831:Animals, Newborn; D000945:Antigens, Differentiation, T-Lymphocyte; D017252:CD3 Complex; D015704:CD4 Antigens; D016827:CD8 Antigens; D007111:Immunity, Cellular; D008213:Lymphocyte Activation; D051379:Mice; D008819:Mice, Nude; D016853:Muromonab-CD3 / Q000008:administration & dosage / Q000633:toxicity*; D011948:Receptors, Antigen, T-Cell; D016176:T-Lymphocyte Subsets / Q000166:cytology / Q000276:immunology; D013950:Thymus Gland / Q000033:anatomy & histology / Q000166:cytology; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
chemical_list: D000945:Antigens, Differentiation, T-Lymphocyte; D017252:CD3 Complex; D015704:CD4 Antigens; D016827:CD8 Antigens; D016853:Muromonab-CD3; D011948:Receptors, Antigen, T-Cell; D014409:Tumor Necrosis Factor-alpha